Cited by 602Blood Coagulation and Thrombosis MechanismsAcute Myocardial Infarction ResearchBlood properties and coagulation

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women: Evidence for the Fibrinolytic System as an Independent Primary Risk Factor

Thögersen, Anna M., Jansson, Jan-Håkan, Boman, Kurt, Nilsson, Torbjörn K., Weinehall, Lars, Huhtasaari, Fritz, Hallmans, Göran·1998·Circulation

DOI 10.1161/01.cir.98.21.2241

Open this paper in CoChat — free account

Abstract

Background —In patients with established ischemic heart disease, prospective cohort studies have indicated that plasminogen activator inhibitor (PAI-1), the inhibitor of the fibrinolytic system, may predict cardiovascular events. So far, there have been no primary prospective studies of PAI-1. Methods and Results —The aim of the present study was to test whether plasma levels of PAI-1, tissue-type plasminogen activator (tPA), von Willebrand factor (vWF), and thrombomodulin (TM) could predict the occurrence of a first acute myocardial infarction (AMI) in a population with high prevalence of coronary heart disease by use of a prospective nested case-control design. Mass concentrations of PAI-1 and tPA were significantly higher for the 78 subjects who developed a first AMI compared with the 156 references matched for age, sex, and sampling time; for tPA, this increase was independent of smoking habits, body mass index, hypertension, diabetes, cholesterol, and apolipoprotein A-I. The ratio of quartile 4 to 1 for tPA was 5.9 for a patient to develop a first AMI. The association between tPA and AMI was seen in both men and women. Increased levels of vWF were associated with AMI in a univariate analysis. High levels of TM were associated with AMI in women but not in men. Conclusions —The plasma levels of PAI-1, tPA, and vWF are associated with subsequent development of a first AMI; for PAI-1 and tPA, this relation was found in both men and women. For tPA but not for PAI-1 and vWF, this association is independent of established risk factors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1161/01.cir.98.21.2241

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Coronary Plaque Disruption
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
An updated coronary risk profile. A statement for health professionals.
Anderson, K. M., Wilson, P. W., Odell, P. M., & Kannel, W. B. (1991) · Circulation · doi:10.1161/01.cir.83.1.356 · Cited by 1,834
Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris
Thompson, S. G., Kienast, J., Pyke, S., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,819
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., de Faire, U., Dahlén, G. H., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
MEADE, T. (1993) · The Lancet · doi:10.1016/0140-6736(93)92062-x · Cited by 711
Endogenous tissue-type plasminogen activator and risk of myocardial infarction
Ridker, P. M., Vaughan, D. E., Manson, J., Hennekens, C. H., & Stampfer, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)90998-v · Cited by 580
Fibrinolytic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients With Angina Pectoris
Juhan-Vague, I., Pyke, S., Alessi, M., Jespersen, J., Haverkate, F., & Thompson, S. G. (1996) · Circulation · doi:10.1161/01.cir.94.9.2057 · Cited by 551
von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.
Jansson, J., Nilsson, T., & Johnson, O. (1991) · Heart · doi:10.1136/hrt.66.5.351 · Cited by 356
Self-citation
Clearance of Tissue Plasminogen Activator (TPA) and TPA/Plasminogen Activator Inhibitor Type 1 (PAI-1) Complex: Relationship to Elevated TPA Antigen in Patients With High PAI-1 Activity Levels
Chandler, W. L., Alessi, M. C., Aillaud, M. F., Henderson, P., Vague, P., & Juhan-Vague, I. (1997) · Circulation · doi:10.1161/01.cir.96.3.761 · Cited by 245

Show all 30 references

Research works printed but not linked: 10

10.1161/circ.83.1.1984895 · DOI
10.1161/circ.92.3.657 · DOI
10.1161/circ.94.9.2052 · DOI
10.1161/circ.90.1.8026046 · DOI
Amiral J, Adam M, Mimilia F, Larrivaz I, Chambrette B, Boffa MC. A new assay for soluble forms of thrombomodulin in plasma. Thromb Haemostas. 1991;947:65. Abstract.
10.1161/atv91.12.9.1525121 · DOI
10.1161/circ.88.5.8222095 · DOI
10.1161/circ.94.9.2057 · DOI
10.1161/atvb.15.9.1432 · DOI
10.1161/circ.96.3.761 · DOI

Sorted by citations

Items 401–500 of 597

Changes in haemostatic and platelet activation markers in non-dipper hypertensive patients
Agorasti, A., Mourvati, E., Trivellas, T., Papadopoulos, V. P., Bazntiara, I., Christoforidou, A., & Passadakis, P. (2011) · International Urology and Nephrology · doi:10.1007/s11255-011-9926-9 · Cited by 10
Fatty Acid-Induced Production of Plasminogen Activator Inhibitor-1 by Adipose Macrophages Is Greater in Middle-Aged Versus Younger Adult Participants
Esterson, Y. B., Kishore, P., Koppaka, S., Li, W., Zhang, K., Tonelli, J., Lee, D.-E., Kehlenbrink, S., Lawrence, S., Crandall, J. P., et al. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls200 · Cited by 9
“PAI-1 concentrations are correlated with increased cardiovascular disease risk (16,17) and may contribute to”
Background
The relationship between cardiometabolic and hemostatic variables: influence of race
PERRY, A. C., Wang, X., Goldberg, R., Ross, R., & Jackson, L. (2008) · Metabolism · doi:10.1016/j.metabol.2007.09.001 · Cited by 10
“Previous studies have linked fibrinogen, PAI-1, and the tPA/PAI-1 complex with diabetes [9] and cardiovascular events [25-27]; however, we simultaneously examined the impact of CMV on 3 different hemostatic variables in a biracial group of young overweight/obese women.”
Background
Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure
Sakamoto, M., Suzuki, H., Hayashi, T., Iuchi, H., Isaka, T., Sakamoto, N., Kayama, Y., Tojo, K., Yoshimura, M., & Utsunomiya, K. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-118 · Cited by 11
“Plasma levels of PAI-1 were reported to predict the occurrence of a first acute myocardial infarction and reinfarction [23].”
Background
Adipose tissue, inflammation and atherosclerosis
Rohla, M., & Weiss, T. W. (2014) · Clinical Lipidology · doi:10.2217/clp.13.80 · Cited by 11
The plasma levels of plasminogen activator inhibitor-1 in subjects with white coat hypertension
Çoban, E., & Özdoğan, M. (2004) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2004.00119.x · Cited by 10
Effects of four different regimens of hormone replacement therapy on hemostatic parameters: A prospective randomized study
Taner, M. Z., Özpolat, E., Taşkıran, Ç., Onan, M. A., Gursel, T., Karabulut, E., Gursoy, R., & Himmetoğlu, Ö. (2005) · Maturitas · doi:10.1016/j.maturitas.2005.05.010 · Cited by 10
Resistin Contribution to Cardiovascular Risk in Chronic Kidney Disease Male Patients
Romejko, K., Rymarz, A., Szamotulska, K., Bartoszewicz, Z., Rozmysłowicz, T., & Niemczyk, S. (2023) · Cells · doi:10.3390/cells12070999 · Cited by 9
Effect of cycling in the heat for 164 km on procoagulant and fibrinolytic parameters
Kupchak, B. R., McKenzie, A. L., Luk, H., Sáenz, C., Kunces, L. J., Ellis, L. A., Vingren, J. L., Lee, E. C., Ballard, K. D., Johnson, E. C., et al. (2015) · European Journal of Applied Physiology · doi:10.1007/s00421-015-3107-y · Cited by 9
Peroxisome proliferator-activated receptor-γ and the endothelium: implications in cardiovascular disease
Magri, C. J., Gatt, N., Xuereb, R. G., & Fava, S. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.140 · Cited by 9
p38 Mitogen-Activated Protein Kinase Is Required for Glucosamine-Induced Endothelial Nitric Oxide Synthase Uncoupling and Plasminogen-Activator Inhibitor Expression
Wu, Z., Xiong, Y., Gajanayake, T., Ming, X., & Yang, Z. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-0016 · Cited by 9
Effects of different protein sources on plasminogen inhibitor-1 and factor VII coagulant activity added to a fat-rich meal in type 2 diabetes.
Mortensen, L. S., Thomsen, C., & Hermansen, K. (2010) · The Review of Diabetic Studies · doi:10.1900/rds.2010.7.233 · Cited by 9
“Considerable evidence indicated that a high level of PAI-1 is a risk factor of CHD [3, 4].”
Background
NAFLD and Cardiovascular Disease: Can the Real Association Be Determined?
Trivedi, I., & Rinella, M. E. (2014) · Current Hepatology Reports · doi:10.1007/s11901-014-0231-9 · Cited by 9
The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase
Nilsson, J. B., Boman, K., Jansson, J.-H., Nilsson, T., & Näslund, U. (2007) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-007-0086-9 · Cited by 9
“Von Willebrand factor plays a key-role in the initial phase of the development of a myocardial infarction, and high levels have been shown to be a risk factor for both a first [ 10 ] and recurrent [13, 14] myocardial infarctions.”
BackgroundSelf-citation
Leukocyte telomere length and hemostatic factors in a South African cohort: the SABPA Study
von Känel, R., Malan, N. T., Hamer, M., van der Westhuizen, F. H., & Malan, L. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12733 · Cited by 9
High Factor VIII Activity, High Plasminogen Activator Inhibitor 1 Antigen Levels and Low Factor XII Activity Contribute to a Thrombophilic Tendency in Elderly Venous Thromboembolism Patients
Gary, T., Hafner, F., Froehlich, H., Stojaković, T., Scharnagl, H., Pilger, E., & Brodmann, M. (2010) · Acta Haematologica · doi:10.1159/000321530 · Cited by 9
“Therefore, low factor XII activity should affect the fibrinolytic capacity and increases the risk of thrombotic events in the arterial system.One of the primary regulators of the fibrinolytic system is plasminogen activator inhibitor 1 (PAI 1). Overexpression of PAI 1 may lead to impaired activity of the fibrinolytic…”
Background
Markers of hypercoagulation and von Willebrand factor in postmenopausal women with unstable coronary artery disease. Discriminatory ability regarding unstable coronary artery disease and coronary atherosclerosis using receiver operating characteristics
Nielsen, N. E., Siegbahn, A., & Swahn, E. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00715.x · Cited by 9
Surgical stress induces acute coronary release of tissue‐type plasminogen activator in the pig
Österlund, B., Holmgren, A., Häggmark, S., Jern, C., JOHANSSON, G., Seeman-Lodding, H., & Biber, B. (2000) · Acta Anaesthesiologica Scandinavica · doi:10.1034/j.1399-6576.2000.441007.x · Cited by 9
Endogenous NO Regulates Plasminogen Activator Inhibitor-1 During Angiotensin-Converting Enzyme Inhibition
Brown, N. J., Muldowney, J. A. S., & Vaughan, D. E. (2006) · Hypertension · doi:10.1161/01.hyp.0000202478.79587.1a · Cited by 9
Fast screening of biological fluids for cytokines and adipokines using stochastic sensing
Gugoaşă, L. A., Staden, R. S., Dima, A., Vișan, C. A., Streinu‐Cercel, A., Biris, A. R., & Calenic, B. (2015) · Microelectronic Engineering · doi:10.1016/j.mee.2015.08.007 · Cited by 8
Correlation Between PAI-1 Gene 4G/5G Polymorphism and the Risk of Thrombosis in Ph Chromosome-Negative Myeloproliferative Neoplasms
Zhang, X., Cai, X., & Pan, J. (2020) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029620935207 · Cited by 8
Impacts of circulating microRNAs in exercise-induced vascular remodeling
Guilder, G. P. V., Preston, C. C., Munce, T. A., & Faustino, R. S. (2021) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00894.2020 · Cited by 8
Pharmacogenomics of Renin Angiotensin System Inhibitors in Coronary Artery Disease
Tsikouris, J. P., & Peeters, M. J. (2007) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-007-6026-2 · Cited by 8
Weight loss and vascular inflammatory markers in overweight women with and without polycystic ovary syndrome
Moran, L., Noakes, M., Wittert, G., Clifton, P. M., & Norman, R. J. (2012) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2012.07.013 · Cited by 8
Epistatic Interactions in Genetic Regulation of t-PA and PAI-1 Levels in a Ghanaian Population
Penrod, N. M., Poku, K. A., Vaughn, D. E., Asselbergs, F. W., Brown, N. J., Moore, J. H., & Williams, S. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016639 · Cited by 8
“Clinical evidence indicates that plasma concentrations of t-PA and PAI-1 can also serve as biomarkers of first myocardial infarction [7,8], atherosclerosis [9], ischemic stroke [10] and ischemic heart disease [11].”
Background
Suboptimal glycaemic control enhances the risk of impaired prothrombotic state in youths with type 1 diabetes mellitus
Kyrgios, I., Maggana, I., Giza, S., Stergidou, D., Mouzaki, K., Kotanidou, E. P., Papadakis, E. S., & Galli‐Τsinopoulou, A. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114528821 · Cited by 8
Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor–1 concentration in adults from the Veterans Affairs Diabetes Trial
Zimering, M. B., Anderson, R. J., Luo, P., & Moritz, T. E. (2008) · Metabolism · doi:10.1016/j.metabol.2008.06.012 · Cited by 8
Cerebrovascular gene expression in spontaneously hypertensive rats
Grell, A.-S., Frederiksen, S., Edvinsson, L. I., & Ansar, S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184233 · Cited by 8
“Consequently, Serpine1 plays a role in maintaining the fibrin blood clot and the risk of having a stroke [41,42].”
Background
Plasminogen activator inhibitor-1 expression and secretion are stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytes
Kralisch, S., Klein, J. C., Lössner, U., Blüher, M., Paschke, R., Stümvoll, M., & Faßhauer, M. (2006) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2006.04.027 · Cited by 8
The effects of 12 weeks of HMR 3339, a novel selective estrogen receptor modulator, on markers of coagulation and fibrinolysis: A randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal women
Vogelvang, T. E., Mijatovic, V., Kenemans, P., EMEIS, J. J., Heijst, J. A., & van der Mooren, M. J. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.02.083 · Cited by 8
Diabetic cardiomyopathy and COVID-19: intersecting pathways and amplified cardiovascular risk
Prakash, S., Choudhury, P., & Bisht, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1683159 · Cited by 7
Differences in Clinical and Dietary Characteristics, Serum Adipokine Levels, and Metabolomic Profiles between Early- and Late-Onset Gout
Suh, Y. S., Noh, H. S., Kim, H., Cheon, Y., Kim, M., Lee, H., Kim, H.-O., & Lee, S.-I. (2021) · Metabolites · doi:10.3390/metabo11060399 · Cited by 7
“Elevated plasma PAI-1 levels have been associated with impaired fibrinolytic activity in cardiovascular disease [20].”
Background
Genetic markers: Potential candidates for cardiovascular disease
Rather, R. A., & Dhawan, V. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.251 · Cited by 8
MicroRNA‑30b protects myocardial cell function in patients with acute myocardial ischemia by targeting plasminogen activator inhibitor‑1
Li, B., Hu, J., & Chen, X. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6039 · Cited by 7
Clinical considerations in the management of non-alcoholic steatohepatitis cirrhosis pre- and post-transplant: A multi-system challenge
Steggerda, J. A., Mahendraraj, K., Todo, T., & Noureddin, M. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i28.4018 · Cited by 8
Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy
Hemelaar, M., Kenemans, P., Hack, C. E., Klipping, C., & van der Mooren, M. J. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318093e65a · Cited by 7
Relationship of coagulation and fibrinolytic variables with arterial structure and function in Africans
Pieters, M., Boshuizen, H. C., de Lange, Z., Schutte, A. E., Schutte, R., Greeff, M., & Ariëns, R. A. S. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.04.021 · Cited by 7
Effects of Atenolol or Losartan on Fibrinolysis and von Willebrand Factor in Hypertensive Patients With Left Ventricular Hypertrophy
Boman, K., Hernestål-Boman, J., Andersson, J. S. O., Olofsson, M., & Dahlöf, B. (2009) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029609349501 · Cited by 7
Self-citation
Quantitative Measurement of Carotid Atherosclerosis in Relation to Levels of Von Willebrand Factor and Fibrinolytic Variables in Plasma -- A 2-year Follow-Up Study
Nilsson, T. K., Spence, J. D., Nilsson, P. M., Eliasson, M., Jansson, J., & Boman, K. (2002) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670200900406 · Cited by 7
Self-citation
Metabolic syndrome and risk factors for cardiovascular disease: are nonagenarians protected?
Study, F. T. L. H. A., Frisard, M. I., Rood, J. C., Fang, X., Su, J., Welsh, D. A., Jazwinski, S. M., & Ravussin, É. (2009) · AGE · doi:10.1007/s11357-008-9082-z · Cited by 7
Circulating endothelial cells in health and disease: how do we best quantify them?
Shantsila, E., & Lip, G. Y. H. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.02985.x · Cited by 7
Elevated plasma homocysteine: cause or consequence of myocardial infarction?
Hultdin, J., Thøgersen, A. M., Jansson, J.-H., Nilsson, T., Weinehall, L., & Hallmans, G. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01415.x · Cited by 7
Self-citation
Minimally oxidized low-density lipoprotein regulates hemostasis factors of brain capillary endothelial cells
Kim, J. A., Tran, N., Berliner, J. A., & Fisher, M. (2003) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2003.09.006 · Cited by 7
Effects of carvedilol or metoprolol on PAI-1, tPA-mass concentration or Von Willebrand factor in chronic heart failure - a COMET substudy
Boman, K., Jansson, J., Nilsson, T., Swedberg, K. B., Cleland, J. G. F., & Poole-Wilson, P. A. (2009) · Thrombosis Research · doi:10.1016/j.thromres.2009.08.010 · Cited by 7
“[22,24,28].”
BackgroundSelf-citation
Circulating thrombotic and haemostatic components in patients with coronary artery disease
Shalia, K. K., Shah, V. K., Mashru, M. R., Soneji, S. L., Vasvani, J. B., Payannavar, S., Walvalkar, A., Mokal, R. A., Mithbawkar, S. M., Kudalkar, K. V., et al. (2010) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-010-0005-2 · Cited by 7
Dyslipidemia in Type 2 Diabetes and the Effects of Thiazolidinediones
Bell, D. (2003) · The Endocrinologist · doi:10.1097/01.ten.0000098612.88907.4b · Cited by 8
El adipocito como órgano endocrino. Implicaciones fisiopatológicas y terapéuticas
Pérez-Mayorga, M. (2007) · Revista Med · Cited by 7
Tissu adipeux, inflammation et athérome
Meier, C. A., & Thalmann, S. (2007) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/s0001-4079(19)33028-6 · Cited by 7
Effect of antihypertensive therapy on endothelial markers in newly diagnosed Stage 1 hypertension: a randomized single-centre study
Şendur, M. A. N., Guven, G. S., Yorgun, H., Ateş, A. H., Canpolat, U., Sunman, H., Karahan, S., Kaya, B., & Aytemir, K. (2014) · The Anatolian Journal of Cardiology · doi:10.5152/akd.2014.4793 · Cited by 6
“Additionally, ‘plasminogen activator inhibitor-1’ (PAI-1), which is secreted from the endothelium, impairs the balance between normal haemostasis and fibrinolysis and thus contributes to the prothrombotic state (8).”
Background
Atherothrombosis in diabetes – its evolution and management
Drouet, L. O. (1999) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.1999.0010s2037.x · Cited by 6
Impaired Fibrinolysis in Angiographically Documented Coronary Artery Disease
Fernandes, A. B., Lima, L. M., Sousa, M. O., de Toledo, V. D. P. C. P., Kazmi, R. S., Lwaleed, B. A., & Ferriani, M. D. G. C. (2015) · Advances in Hematology · doi:10.1155/2015/214680 · Cited by 6
“Increased levels of PAI-1 have been described in patients with CAD after myocardial infarction (MI) [3] and are considered a risk factor for recurrence [4].”
Background
Insulin resistance predicts the risk for recurrent coronary events in post-infarction patients
Szepietowska, B., McNitt, S. A., Kutyifa, V., Ryan, D., Corsetti, J. P., Sparks, C. E., Moss, A. J., & Zaręba, W. (2015) · Cardiology Journal · doi:10.5603/cj.a2015.0014 · Cited by 6
“Elevated plasma level of PAI-1 has been shown to predict risk for recurrent coronary events and first MI [27, 28], but its predictivity is attenuated after adjustment for IR [29].”
Background
Fibrinolytic Activity and Platelet Function in Subjects with Obstructive Sleep Apnoea and a Patent Foramen Ovale: Is There an Option for Prevention of Ischaemic Stroke?
Reggiani, M., Karttunen, V., Wartiovaara‐Kautto, U., Riutta, A., Uchiyama, S., & Hillbom, M. (2012) · Stroke Research and Treatment · doi:10.1155/2012/945849 · Cited by 6
“One study has nevertheless indicated that high levels of PAI1 preceded the onset of a first myocardial infarction [25].”
Background
Significant inverse associations of serumn-6 fatty acids with plasma plasminogen activator inhibitor-1
Lee, S., Curb, J. D., Kadowaki, T., Evans, R. G., Miura, K., Takamiya, T., Shin, C., El‐Saed, A., Choo, J., Fujiyoshi, A., et al. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511003199 · Cited by 6
Monthly haemostatic factor variability in women and men
Hill, A. M., Stewart, P. W., Fung, M. K. Y., Kris‐Etherton, P. M., Ginsberg, H. N., Tracy, R. P., Pearson, T. A., Lefevre, M., Reed, R. G., Elmer, P. J., et al. (2014) · European Journal of Clinical Investigation · doi:10.1111/eci.12235 · Cited by 6
“Given the relatively stringent requirements for blood collection for a PAI-1 activity assay, coupled with the multi-center nature of DELTA and the fact that much of epidemiological data linking PAI-1 to diabetes and cardiovascular risk was assembled with assays for either uncomplexed PAI-1 or total PAI-1 [19], we chos…”
Fibrinolytic effects of peroneal nerve stimulation in patients with lower limb vascular disease
Barnes, R., Madden, L. A., & Chetter, I. C. (2015) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000000409 · Cited by 6
The effect of acute aerobic exercise on hemostasis in obstructive sleep apnea
Martin, R. A., Strosnider, C. L., Giersch, G. E. W., Womack, C. J., & Hargens, T. A. (2017) · Sleep And Breathing · doi:10.1007/s11325-017-1477-6 · Cited by 6
“showed that elevated plasma levels of PAI-1 and tPA antigen were associated with a first acute myocardial infarction for men and women (56).”
Background
Acute coronary syndromes: from the laboratory markers to the coronary vessels.
Palazzuoli, A., Iovine, F., Chiara, S., & Nuti, R. (2007) · PubMed Central · Cited by 6
New in vitro model to study high glucose-dependent endothelial dysfunctions
Donnini, D., Terra, E. D., Ambesi‐Impiombato, F. S., & Curcio, F. (2003) · Biochimie · doi:10.1016/s0300-9084(03)00116-0 · Cited by 6
Improving the prognosis of diabetic patients: Evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) therapy
Bedigian, M. P. (2000) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.3317/jraas.2000.050 · Cited by 6
“These markers reflect endothelial dysfunction and elevations in their plasma levels have been shown to be premonitory for myocardial infarction.(14) Insulin levels, which are indicative of insulin sensitivity and which have been associated with cardiovascular risk in prospective studies, will also be measured.”
Background
Mural thrombus of the aorta in association with homozygous plasminogen activator inhibitor type 1 (PAI-1)-675(4G) and heterozygous GP Ia 807C/T genotypes
Beldi, G., Bissat, A., Eugster, T., Gürke, L., Stierli, P., & Huber, A. (2002) · Journal of Vascular Surgery · doi:10.1067/mva.2002.126549 · Cited by 6
Novel risk factors for coronary artery disease
Abramson, B. L., Batchelor, W., Cantor, W. J., Casella, L., Chisholm, R. J., Chow, C.-M., Dorian, P., Fitchett, D., Freeman, M. R., Goodman, S. G., et al. (2001) · Cited by 6
Increase in plasma plasminogen activators inhibitor type 1 concentration after fibrinolytic treatment in patients with acute myocardial infarction is associated with 4G/5G polymorphism of PAI‐1 gene
Młynarska, A., Waszyrowski, T., & Kasprzak, J. D. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.01990.x · Cited by 6
Relationship between fibrinolytic and metabolic variables: a study in patients attending a lipid clinic
Mussoni, L., Baldassarre, D., Mannucci, L., Sirtori, C. R., & Tremoli, E. (2000) · Annals of Medicine · doi:10.3109/07853890009011763 · Cited by 6
Plasminogen activator inhibitor-1 promoter activity in adipocytes is not influenced by the 4 G/5 G promoter polymorphism and is regulated by a USF-1/2 binding site immediately preceding the polymorphic region
Zietz, B., Drobnik, W., Herfarth, H. H., Buechler, C., Schölmerich, J., & Schaeffler, A. (2004) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0320155 · Cited by 6
Plasminogen activator inhibitor 1 promotes aortic aging–like pathophysiology in humans and mice
Khoddam, A., Kalousdian, A., Eren, M., Soberanes, S., Decker, A., Lux, E., Zywicki, B. W., Dinh, B., Boztepe, B., Cheema, B. S., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci196714 · Cited by 6
Periodontitis and Systemic Health: An Interconnected Relationship
Diehl, D. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-03176-1_5 · Cited by 7
Plasma Levels of Tissue-Type Plasminogen Activator (tPA) in Normal Aging and Alzheimer's Disease: Links With Cognition, Brain Structure, Brain Function and Amyloid Burden
Tomadesso, C., de Lizarrondo, S. M., Ali, C., Landeau, B., Mézenge, F., Perrotin, A., Sayette, V. D. L., Vivien, D., & Chételat, G. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.871214 · Cited by 7
Plasminogen Activator Inhibitor 1 Activity and Other Coronary Risk Factors
von Eyben, F. E., Mouritsen, E., Holm, J., Montvilas, P., Dimcevski, G., Suciu, G., Rasmussen, I. H., Kristensen, L. L., & von Eyben, R. (2005) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/107602960501100106 · Cited by 5
Headache in Children: Selected Factors of Vascular Changes Involved in Underlying Processes of Idiopathic Headaches
Sordyl, J., Małecka‐Tendera, E., Sarecka‐Hujar, B., & Kopyta, I. A. (2020) · Children · doi:10.3390/children7100167 · Cited by 5
Signaling mechanisms for oxidized LDL-induced oxidative stress and the upregulation of plasminogen activator inhibitor-I in vascular cells
Sangle, G. V., & Shen, G. X. (2010) · Clinical Lipidology · doi:10.2217/clp.10.6 · Cited by 5
Testosterone and cardiovascular disease
Channer, K. S., & Jones, T. H. (2012) · Cambridge University Press eBooks · doi:10.1017/cbo9781139003353.011 · Cited by 5
Chronobiology of acute myocardial infarction molecular biology
Takeda, N., & Maemura, K. (2007) · Biological Rhythm Research · doi:10.1080/09291010600906208 · Cited by 5
“High plasma levels of PAI-1 and tPA are considered to predict a first AMI (Thogersen et al. 1998), suggesting the fundamental role of the fibrinolytic cascade in the pathogenesis of AMI.”
Background
Hormone Therapy and Cardiovascular Disease
Chen, F. (2006) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/s1028-4559(09)60245-x · Cited by 5
Genpolymorphismen der Hämostase und Koronarrisiko
Hellstern, P., Bach, J., Haubelt, H., Preiss, A., Winkelmann, B. R., & Senges, J. (2001) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/pl00002197 · Cited by 5
Coagulation Disorders
Moll, S., & White, G. (2006) · Humana Press eBooks · doi:10.1007/978-1-59259-963-9_90 · Cited by 5
Fibrinolysis and diabetic vascular disease: roles of plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor
Aso, Y. (2006) · Future Lipidology · doi:10.2217/17460875.1.4.429 · Cited by 5
“Elevated plasma PAI-1 may play a role in the development of atherothrombosis in obese patients with Type 2 diabetes independently of other known cardiovascular risk factors [59].”
Background
Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate
Evans, M., McEwan, P. C., Peters, J. R., & Currie, C. J. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1462-8902.2004.00340.x · Cited by 5
Estrogen receptor-α thymidine and adenine repeat polymorphism and endothelial fibrinolytic regulation in postmenopausal women
Hoetzer, G. L., Irmiger, H. M., Stauffer, B. L., & DeSouza, C. A. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.01.028 · Cited by 4
Vascular biomarkers in the metabolic syndrome
Thande, N. K., & Rosenson, R. S. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.2 · Cited by 4
Primary Prevention of Ischemic Heart Disease
Meadows, J. L., Danik, J. S., & Albert, M. A. (2007) · Elsevier eBooks · doi:10.1016/b978-1-4160-3358-5.50015-2 · Cited by 4
Association of sleep onset of acute coronary syndrome with sleep apnea syndrome and abnormal diurnal variation of hemostasis and adipokine levels
Yano, Y., Ohmori, T., Shimada, K., Sakata, Y., & Kario, K. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e328355e885 · Cited by 4
Prothrombotic status in COVID‑19 with diabetes mellitus (Review)
Mitroi, R. M., Pădureanu, V., Mitrea, A., Timofticiuc, D. C. P., Rosu, M. M., Clenciu, D., Enescu, A., Pădureanu, R., Cojan, T. Ș. Ț., & Vladu, I. M. (2023) · Biomedical Reports · doi:10.3892/br.2023.1647 · Cited by 4
“Furthermore, an assumption has been made about the substantial impact of hyperglycemia and hyperinsulinemia on gene transcription (32).”
Association of coronary atherosclerosis with insulin resistance in patients with impaired glucose tolerance
Stochmal, E., Szurkowska, M., Czarnecka, D., Stochmal, A., Klecha, A., KAWECA-JASZCZ, K., & Szybiński, Z. (2005) · Acta Cardiologica · doi:10.2143/ac.60.3.2005012 · Cited by 4
Changes in plasma C-reactive protein and hemostatic factors prior to and after a first myocardial infarction with a median follow-up time of 8 years
Thøgersen, A. M., Nilsson, T., Weinehall, L., Boman, K., Eliasson, M., Hallmans, G., & Jansson, J. (2009) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32832a5fd1 · Cited by 4
Self-citation
Thrombin activatable fibrinolysis inhibitor
Yildirim, M. N., Selçoki, Y., Uysal, S., Nacar, A. B., Demirçelik, B., Aydın, H. İ., & Eryonucu, B. (2013) · Herz · doi:10.1007/s00059-013-3942-8 · Cited by 4
Cerebral atherosclerosis: a biomarker profile
Tanashyan, M. M., Лагода, О. В., Евдокименко, А. Н., Шабалина, А. А., & Раскуражев, А. А. (2018) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro20181185123 · Cited by 4
Bioinformatics-based analysis of the involvement of AC005550.3, RP11-415D17.3, and RP1-140K8.5 in homocysteine-induced vascular endothelial injury.
Li, J., Luo, M., Xie, N., Wang, H., & Wang, J. (2018) · Europe PMC (PubMed Central) · Cited by 4
Platelet hyperaggregability persists even after the improvement of increased blood coagulation and impaired fibrinolysis with the stabilization of symptoms in patients with unstable angina
Miyamoto, S., Ogawa, H., Sakamoto, T., Soejima, H., Takazoe, K., Shimomura, H., Kajiwara, I., Yoshimura, M., Kugiyama, K., Nakamura, S., et al. (2001) · International Journal of Cardiology · doi:10.1016/s0167-5273(01)00515-0 · Cited by 4
ATVB In Focus
Cohen, R. A. (2004) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000137187.16206.79 · Cited by 4
A part le fibrinogène, les facteurs/marqueurs d’hémostase ont-ils aussi une place pour évaluer le risque d’accident cardiovasculaire ischémique ?
Drouet, L. O., & Sollier, C. B. D. (2005) · Therapies · doi:10.2515/therapie:2005018 · Cited by 3
Adipokines: linking obesity and cardiovascular disease
Bell-Anderson, K. S. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.3.1.61 · Cited by 3
Non-Atherosclerotic Causes of Acute Coronary Syndrome and Management of The Patients
Alihanoğlu, Y. İ., Kılıç, İ. D., & Yıldız, B. S. (2013) · Electronic Journal of General Medicine · doi:10.29333/ejgm/82300 · Cited by 3
Gene expression of fibrinolytic markers in coronary thrombi
Nordeng, J., Solheim, S., Åkra, S., Schandiz, H., Hoffmann, P., Roald, B., Bendz, B., Arnesen, H., Helseth, R., & Seljeflot, I. (2022) · Thrombosis Journal · doi:10.1186/s12959-022-00383-1 · Cited by 3
“Plasma levels of tPA and PAI-1 have been found to predict myocardial infarction, and high levels associate with poor prognosis in populations with high prevalence of coronary artery disease [7], and in patients with chronic coronary syndrome [8].”
Background
Associations between antipsychotics-induced weight gain and brain networks of impulsivity
Grosu, C., Klauser, P., Dwir, D., Khadimallah, I., Alemán‐Gómez, Y., Laaboub, N., Piras, M., Fournier, M., Preisig, M., Conus, P., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02881-4 · Cited by 3
Inhibition of plasminogen activator inhibitor-1 expression in vascular smooth muscle cells by protoporphyrins through a heme oxygenase-independent mechanism
Long, X., & Schafer, A. I. (2008) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-9724-6 · Cited by 3
“Recent evidence suggests that an elevated level of PAI-1 is an important risk factor for vascular diseases [2, 3]. Elevated level of plasma PAI-1 is associated with increased coronary events [4, 5 ]. It has also been found that PAI-I expression is increased in atherosclerotic lesions [6‐8], contributing to coronary ar…”
Evaluating the Cardiovascular Effects of the Thiazolidinediones and Their Place in the Management of Type 2 Diabetes in Relation to the Metabolic Syndrome
Drexler, A., Nesto, R. W., Abrahamson, M. J., Bakris, G. L., Bell, D. S. H., Brunzell, J. D., Dandona, P., Davidson, J. A., Fonseca, V. A., Fowler, M. B., et al. (2005) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2005.3.147 · Cited by 3
Fibrinolytic risk factor clustering and insulin resistance in healthy male relatives of men with intermittent claudication
Parry, D. J., Grant, P. J., & Scott, D. J. A. (2006) · British journal of surgery · doi:10.1002/bjs.5270 · Cited by 3
Valor pronóstico de la concentración del inhibidor de la fibrinolisis activable por trombina y del polimorfismo C1040T en el infarto agudo de miocardio tratado con fibrinolisis
González, F. J., Caturla, J., Fernández, M., Carrasco, R., Marco, P., Sánchez, J., & Benlloch, S. (2010) · Medicina Intensiva · doi:10.1016/j.medin.2010.05.001 · Cited by 3
“Genotipo Thr325Ile 8 (15) 27 (52) o0,01”
Associations of Thrombotic-Hemostatic Factors with Cardiovascular Disease~!2009-10-29~!2009-12-22~!2010-04-08~!
Lioudaki, E., & Ganotakis, E. S. (2012) · The Open Clinical Chemistry Journal · doi:10.2174/1874241601003010025 · Cited by 3
“tPA antigen and PAI-1 have been positively associated with CV events [45,122,137,163,164].”
Background

Authors: Thögersen, A. M., Jansson, J.-H., Boman, K., Nilsson, T. K., Weinehall, L., Huhtasaari, F., & Hallmans, G.
Affiliations: From the Department of Medicine (A.M.T.), Department of Clinical Chemistry (T.K.N.), and Departments of Nutritional Research and Pathology (G.H.), Umeå University Hospital; Department of Medicine-Geriatric, Skellefteå County Hospital (J.-H.J., K.B.) and Department of Epidemiology and Public Health (L.W.), University of Umeå; and Department of Medicine, Luleå Hospital (F.H.), Sweden.
University Hospital of Umeå (SE)
ORCID: Boman, Kurt
Weinehall, Lars
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1998-11-24
Volume: 98
Issue: 21
Pages: 2241-2247
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.98.21.2241
OpenAlex: W1976057876
Cited by: 602
References: 30
Citations by year: 2026: 3 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 19 · 2021: 10 · 2020: 10 · 2019: 6 · 2018: 14 · 2017: 7 · 2016: 17 · 2015: 12 · 2014: 27 · 2013: 20 · 2012: 19
FWCI: 10.91
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Funders: Umeå Universitet
Topics: Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Health Sciences › Medicine › Hematology › Blood properties and coagulation
Keywords: plasminogen activator inhibitor-1, tissue plasminogen activator, acute myocardial infarction, von Willebrand factor, thrombomodulin, fibrinolysis, coronary artery disease, cardiovascular risk prediction, sex differences, plasma biomarkers
MeSH terms: Adult, Age Factors, Female, Fibrinolysis, Humans, Middle Aged, Myocardial Infarction, Tissue Plasminogen Activator, Predictive Value of Tests, Prospective Studies, Risk Factors, Sex Factors, Sweden, Biomarkers, Plasminogen Inactivators, Incidence, Case-Control Studies, Dehydroepiandrosterone Sulfate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women: Evidence for the Fibrinolytic System as an Independent Primary Risk Factor

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks